Stilla Technologies presents a novel approach for COVID-19 testing combining group testing with digital PCR and publishes the largest comparative study to date for group testing of SARS-CoV-2
The approach significantly reduces costs and increases testing capacity while offering a diagnostic sensitivity greater than the current standard of individual RT-PCR tests
Paris, June 5th, 2020
Stilla Technologies, a leading French provider of pioneering solutions for high‐precision genetic analysis, is offering a new high-throughput and cost-effective testing approach for COVID-19 by combining its digital PCR technology with the group testing method and publishes the largest comparative study to date for group testing of SARS-CoV-2.
“We continue our efforts in the fight against Covid-19 and are proud today to present an innovative approach that greatly increases the testing capacity and meets the highest quality standards. This digital PCR based group testing method has a diagnostic sensitivity superior or equal to the current standard – that is individual RT-PCR testing – for group sizes up to 16 samples. The main benefit of this method is that it reduces the amount of reagent required to test a population by about 80% while reducing costs by as much and increasing test capacities by up to 10 times”, said Rémi Dangla, Co-founder and CEO of Stilla Technologies.